RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without their cancer getting worse. About 813 participants with stage III, IV, or recu…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:01 UTC
-
Engineered virus targets Hard-to-Treat endometrial cancer in early trial
Disease control OngoingThis early-phase trial tests a specially designed virus that may selectively attack cancer cells while sparing healthy ones. The study includes up to 34 people with advanced or recurrent endometrial cancer. The main goal is to find the safest dose and understand side effects, wit…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 07:59 UTC
-
New hope for recurrent ovarian and endometrial cancers: targeted drug shows promise
Disease control OngoingThis study tests a drug called tazemetostat in people whose ovarian or endometrial cancer has returned after previous treatment. The drug works by blocking a protein that helps cancer cells grow. The goal is to see if it can shrink tumors or slow the disease. About 62 participant…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
New drug combo shows promise for advanced endometrial cancer
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard hormone therapy (megestrol acetate) can help control recurrent or metastatic endometrioid endometrial cancer. About 96 adults with grade 1 or 2 cancer that has returned or spread will participate. The goal is to see…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
New drug combo shows promise for hard-to-treat endometrial cancer
Disease control OngoingThis study tests whether adding a third drug (ribociclib) to a two-drug combination (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. The trial involves 90 participants and aims to see if the three-drug combo can shrink tumors or st…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC